차입 증가 → 이자부담 → 수익성 악화
Critical부채가 +121.1% 늘며 이자보상배율이 -13.6x에서 -14.6x로 하락했다. ROE도 -13.2%에서 -17.4%로 낮아져 차입 부담이 수익성을 누르고 있다.
Evidence
부채 YoY +121.1%이자보상배율 -13.6x→-14.6xROE -13.2%→-17.4%
FutureChem
220100 · KOSDAQ₩8,130+3.44%
2026-09-04 closeFutureChem last closed at ₩8,130 (+3.44%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.
Loading chart…
Close
No active signal.
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
D
Overall: 건강관리 235/291 · top 81%
Factor composite · relative position in sector
PER — · PBR 3.41 — own-history percentile 55/100 · 75/100
Open self-history band
PER55/100
PBR75/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 0.65
Distress
Grey
Safe
- Altman Z''
- 0.65
- Beneish M-Score
- -3.37
- Sloan accrual
- -8.34%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
3/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score3/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginPass
- Higher asset turnoverPass
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -19%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Balance sheetWarning
부채총계 급증 (+121%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
KRAs of 2026-09-05건강관리
This stock is in 건강관리: revenue rank 214 of 287, share 0%.
214 / 2870%revenue share
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6퓨쳐켐0%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 13.9
- Median P/B
- 1.47
- Level
- 넓음
- n
- 263
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -54.7%
- Interest coverage
- -14.6x
- Return on equity (ROE)
- -17.3%
Operating margin −5pp
Operating lossInterest coverageBase -14.6x adverse case -15.9x
Return on equity (ROE)Base -17.3% adverse case -20.2%
Revenue −15%
Interest coverage riskInterest coverageBase -14.6x adverse case -12.4x
Return on equity (ROE)Base -17.3% adverse case -16%
Interest rate +2pp
Interest coverage riskInterest coverageBase -14.6x adverse case -9x
Return on equity (ROE)Base -17.3% adverse case -19.3%
Interest coverage limit
Already below the limit by 58.5ppInterest coverage limit at an operating margin of 3.8%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-18Suppliers disclosed by the company in its 2026-03-18 annual report.
Suppliers without disclosed amount
EcgonidineUSDEURScnDOTACITPDVUEOxygenCNYTLCMicroPipet+6 more
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 지대윤13.83%2026-08-24 · 증감 -0.50%p
Connections
AI-extracted related companies · for reference
Suppliers
Competitors
SK바이오팜Price comovement r=0.40 (1 year)Lantheus HoldingsTelix PharmaceuticalsCuriumITM Isotope Technologies MunichNovartis
Same theme
Recent filings
FutureChem's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About FutureChem
- What technical signals does FutureChem (220100) have?
- FutureChem current technical signals: no active technical signal.
- Is FutureChem a cup-and-handle pattern?
- No. FutureChem has no valid cup-and-handle signal right now.
- What are FutureChem's financials and valuation?
- FutureChem's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy